Trazodone for Sleep: What the Evidence Shows

Verdict: Mixed. Some evidence for short-term improvement in sleep onset and maintenance. Long-term efficacy data are sparse. The prescribing volume has far outrun the evidence base.

The claim: trazodone helps you sleep. Physicians prescribe it for this purpose more than for depression, its approved indication. The mismatch between how widely it is prescribed and how well it is studied is the central finding of this audit.

The claim inventory

The clinical claim is straightforward: low-dose trazodone produces sedation and can be used as a sleep aid. This is true in the short term. The broader implied claim, that trazodone is a well-supported, well-characterized sleep medication appropriate for long-term use, is where the evidence falls short. The prescribing volume treats trazodone as though the evidence is settled. It is not.

The off-label framing is worth noting. Trazodone is FDA-approved for major depressive disorder. It has never been approved for insomnia. Off-label prescribing is legal and sometimes well-supported by evidence. But it means the drug was never subjected to regulatory review specific to insomnia, which would have required larger trials, longer durations, and systematic safety evaluation in the insomnia population.

The pharmacology

Trazodone is classified as a serotonin antagonist and reuptake inhibitor (SARI). Its pharmacological profile is dose-dependent, and the profile at sleep doses is different from the profile at antidepressant doses.

At its antidepressant dose range (150-600mg), serotonin reuptake inhibition dominates: the drug increases serotonin availability in the synapse, similar to SSRIs. At the low doses used for sleep (25-100mg), a different set of receptor effects dominate [3]. Histamine H1 receptor antagonism produces sedation, similar to the mechanism of diphenhydramine. Alpha-1 adrenergic receptor antagonism produces additional sedation and also causes orthostatic hypotension. Serotonin 5-HT2A receptor antagonism may promote slow-wave sleep and reduce sleep fragmentation.

In practical terms, low-dose trazodone is pharmacologically closer to an antihistamine with additional receptor effects than to its own antidepressant mechanism. The sleep effect is a side effect of the drug’s receptor binding profile, repurposed as the primary clinical use. The dose at which trazodone is prescribed for sleep is below the range at which it functions as an antidepressant, which means people taking it for sleep are not receiving antidepressant treatment.

What the trials show

The Walsh trial is the largest and most cited RCT for trazodone as a sleep aid [1]. It randomized 306 adults with primary insomnia to trazodone 50mg, zolpidem 10mg, or placebo for two weeks. Trazodone was superior to placebo for subjective sleep quality in the first week. By week two, the difference between trazodone and placebo was no longer statistically significant. Zolpidem maintained its effect through both weeks.

The week-two finding is clinically important. If the sedative effect of trazodone diminishes within two weeks in a controlled trial, the implication for the millions of people taking it nightly for months or years is concerning. The trial was not designed to answer the long-term question, but it raises it sharply. Does continued use beyond two weeks produce continued benefit, or are chronic users taking a drug that lost its sleep effect weeks or months ago while retaining its side effects?

The Cochrane review by Everitt et al. examined antidepressants for insomnia and rated the evidence for trazodone specifically as “very low quality” [5]. The assessment cited small sample sizes, short study durations, high risk of bias, and heterogeneity across trials. “Very low quality” in Cochrane terminology means the reviewers have very little confidence that the true effect lies close to the estimate.

The Jaffer systematic review examined 45 studies of mixed designs, including RCTs, observational studies, and case reports, and reached a somewhat more favorable conclusion: limited evidence suggests short-term efficacy [6]. But the review also acknowledged the methodological limitations. Mendelson’s narrative review reached similar conclusions: the evidence suggests a short-term effect, but the evidence base is thin relative to the prescribing practice [2].

The prescribing-evidence gap

Trazodone is the most commonly prescribed medication for insomnia in the United States. Prescription data suggest it is used more frequently for sleep than all FDA-approved insomnia medications combined. This prescribing volume rests on a small number of short-term trials with modest effect sizes and very low quality ratings from systematic reviewers.

The AASM clinical practice guideline explicitly states there is insufficient evidence to recommend trazodone for the treatment of chronic insomnia [4]. This is not a recommendation against it (as with diphenhydramine). It is a statement that the evidence is not adequate to make a recommendation in either direction. The distinction matters: the guideline panel reviewed the available data and concluded they could not determine whether the benefits outweigh the risks for this indication.

How did the most commonly prescribed insomnia medication end up without enough evidence for a guideline recommendation? The answer is partly historical. Trazodone was already widely used for insomnia before the evidence standards for clinical guidelines were established. Clinicians found it useful, patients reported benefit, and the prescribing practice grew organically. By the time systematic reviewers examined the evidence, the practice was already entrenched.

Where the evidence is stronger

Trazodone has a more logical evidence basis in people with comorbid depression and insomnia, where both the antidepressant and sedative properties serve the clinical picture [2]. In this population, the dual action, even at doses below the full antidepressant range, may provide some benefit to both conditions.

Trazodone also avoids the dependence profile of benzodiazepines and z-drugs (zolpidem, eszopiclone, zaleplon), which is a genuine clinical advantage. It is not a controlled substance, does not produce the same pattern of dose escalation, and carries lower risk of physical dependence. For clinicians appropriately cautious about prescribing controlled substances for a chronic condition, trazodone offers a lower-risk pharmacological option.

Side effects and safety

Common side effects: next-day drowsiness, which is dose-dependent and can impair morning functioning; dry mouth; dizziness; and headache. The next-day drowsiness is clinically significant because insomnia treatment should improve daytime functioning, not trade nighttime wakefulness for morning impairment.

Less common but clinically important: orthostatic hypotension, particularly in older adults, the heaviest users of trazodone for sleep, can cause falls. This is a serious safety concern in the elderly, where falls lead to fractures and hospitalizations. Priapism is rare but requires emergency medical treatment.

Discontinuation after regular use can produce rebound insomnia: worse sleep than baseline in the days after stopping. This sometimes gets interpreted as evidence that the drug was “working” rather than as a withdrawal effect. The rebound pattern can create a cycle where the user resumes the drug to escape withdrawal-related insomnia, mistaking dependency for continued efficacy.

The question of duration

Most prescriptions for trazodone for sleep are written without a defined end date. The drug is started “as needed for sleep” and becomes a nightly fixture. The Walsh trial lasted two weeks and found the effect diminishing by the end of that period [1]. No published trial has examined whether trazodone maintains its sedative effect at three months, six months, or a year of nightly use.

This gap matters because chronic insomnia is, by definition, a long-term condition. A medication prescribed for chronic insomnia should ideally have long-term efficacy data demonstrating that it continues to work for the duration it is prescribed. Trazodone does not have this data. The prescribing practice assumes sustained benefit based on continued subjective reports from patients, but self-reported benefit from a nightly medication does not distinguish between pharmacological effect, placebo effect, habit, and fear of rebound insomnia upon discontinuation.

Tapering off trazodone after months or years of use often produces rebound insomnia that the patient interprets as confirmation that the drug was working. This pattern makes it difficult for both patient and prescriber to distinguish between genuine ongoing benefit and physiological dependency that mimics benefit. A drug can produce withdrawal effects without having been therapeutically effective, and the withdrawal effect, not the therapeutic effect, is what keeps many long-term users from stopping.

How it compares to CBT-I

CBT-I addresses the behavioral and cognitive factors that maintain insomnia: excessive time in bed, conditioned arousal, catastrophizing about sleep consequences. Meta-analyses show large, durable effect sizes maintained at multi-year follow-up. Trazodone produces modest short-term sedation through a pharmacological side effect that may diminish within weeks. The mechanisms are not comparable, and neither are the evidence bases.

The bottom line

Trazodone probably helps sleep modestly in the short term. The evidence base is not strong enough for the prescribing volume it carries. The AASM does not have sufficient evidence to recommend it for chronic insomnia. The Walsh trial suggests the effect may diminish within two weeks, which raises questions about the millions of long-term prescriptions. It avoids the dependence risks of benzodiazepines, which is a genuine advantage, but “safer than benzodiazepines” and “well-supported by evidence” are different claims, and only the first one holds. A patient starting trazodone for sleep should ask their prescriber two questions: how long will I take this, and what is the plan for addressing the insomnia beyond the medication.

If you’re struggling with sleep regularly, speak with a GP or pharmacist before adding supplements or medications. For persistent insomnia, AASM guidelines recommend CBT-I as the first-line treatment. The American Academy of Sleep Medicine has a provider finder at sleepeducation.org.